Healthcare / BiotechnologyNasdaqCM
$7.74
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-18.4M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$46M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-99.3%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-12.6%
FCF / Net income
0.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $43.8M · net income $-35.0M · FCF $-5.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $43.8M | $43.8M | $6.3M | — | — | — | — |
| Net Income | $-35.0M | $-35.0M | $-58.2M | $-76.4M | $-88.2M | $-75.8M | $-55.2M |
| EBITDA | $-40.4M | $-40.4M | $-58.9M | $-77.2M | $-87.3M | $-73.5M | $-53.5M |
| EPS | -4.19 | -4.19 | -15.24 | -2.78 | -3.22 | -13.52 | -105.42 |
| Operating Margin | -95.9% | -95.9% | -954.9% | — | — | — | — |
| Net Margin | -80.1% | -80.1% | -918.0% | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-5.5M | $-5.5M | $-18.4M | $-69.1M | $-77.6M | $-81.9M | $-38.3M |
| Returns | |||||||
| ROE | -99.3% | -99.3% | -331.0% | -207.5% | -83.5% | -40.9% | 66.3% |
| Growth & Yield | |||||||
| Revenue Growth | 589.9% | 589.9% | — | — | — | — | — |
| EPS Growth | 72.5% | 72.5% | -448.2% | 13.7% | 76.2% | 87.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.